Assertio Therapeutics (ASRT) Tops Q3 EPS by 27c, provides guidance

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.18, $0.27 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $49.46 million versus the consensus estimate of $27.02 million.

GUIDANCE:

Assertio Therapeutics sees FY2025 revenue of $110-112 million, versus the consensus of $111.1 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Array Technologies holds investor showcase on balance-of-system strategy
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue